8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Feb 4, 2021)

Filed February 4, 2021For Securities:BIIB

Summary

Biogen Inc. (BIIB) announced on February 4, 2021, the commencement of a private offer to exchange its outstanding 5.200% Senior Notes due 2045, totaling $1.75 billion, for a new series of senior notes and cash. This exchange offer aims to refinance existing debt with new instruments, the terms of which will be determined based on market yields at the time of pricing on February 10, 2021. Investors holding the Old Notes must be qualified institutional buyers or certain non-U.S. persons to participate. The transaction is subject to various conditions, including accounting and tax treatment, as well as specific yield and issuance targets for the new notes. The company also simultaneously launched a cash tender offer for the same notes. These actions indicate Biogen's proactive debt management strategy.

Key Highlights

  • 1Biogen initiated a private exchange offer for its $1.75 billion aggregate principal amount of 5.200% Senior Notes due 2045.
  • 2The exchange involves swapping existing notes for new senior notes and a cash payment.
  • 3The terms of the exchange, including pricing, will be determined on February 10, 2021, based on prevailing market yields.
  • 4Participation is restricted to Qualified Institutional Buyers (QIBs) or certain non-U.S. persons.
  • 5The offer is subject to several conditions, including accounting and tax treatment, and specific yield and issuance targets.
  • 6A concurrent cash tender offer for the same outstanding notes was also announced.
  • 7This move suggests a strategic effort by Biogen to manage its outstanding debt obligations and potentially optimize its capital structure.

Frequently Asked Questions

Biogen is announcing the commencement of a private offer to exchange its existing $1.75 billion of 5.200% Senior Notes due 2045 for new senior notes and cash. They are also launching a simultaneous cash tender offer for the same notes.

Eligibility is limited to investors who are 'qualified institutional buyers' as defined by Rule 144A of the Securities Act, or certain non-U.S. persons, with specific exclusions for retail investors in the EEA/UK and certain Canadian investors.

The total consideration, consisting of new notes and cash, will be determined based on a specific yield to the par call date of the old notes. The issue price of the new notes will be based on a yield to maturity, with both determined by a fixed spread over a reference U.S. Treasury yield at the pricing time, which is set for February 10, 2021, unless extended.

The exchange offer is subject to several conditions, including successful accounting and tax treatment, satisfaction of conditions for the concurrent cash offer, aggregate cash payment limits, minimum and maximum yield conditions for the new notes, and other customary conditions.